Cantor Fitzgerald Estimates Gilead Sciences FY2025 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share estimates for Gilead Sciences in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer expects that the biopharmaceutical company will post earnings of $7.24 per share for the year. Cantor Fitzgerald currently has a "Neutral" rating and a $80.00 price target on the stock. The consensus estimate for Gilead Sciences' current full-year earnings is $4.36 per share.

Other equities analysts have also issued research reports about the company. Wells Fargo & Company upped their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $84.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Wolfe Research initiated coverage on Gilead Sciences in a research report on Friday, November 15th. They set an "outperform" rating and a $110.00 price target for the company. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Finally, Maxim Group downgraded Gilead Sciences from a "buy" rating to a "hold" rating in a research report on Friday, November 8th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $97.96.

Gilead Sciences Trading Up 0.2 %

GILD traded up $0.23 during trading hours on Wednesday, reaching $93.19. The company's stock had a trading volume of 2,731,100 shares, compared to its average volume of 6,716,717. The stock has a market cap of $116.13 billion, a PE ratio of 1,035.89, a P/E/G ratio of 1.29 and a beta of 0.18. Gilead Sciences has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The business's 50-day moving average is $91.62 and its 200-day moving average is $84.57.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion during the quarter, compared to analysts' expectations of $7.01 billion. During the same period last year, the business earned $2.29 earnings per share. Gilead Sciences's revenue was up 7.0% compared to the same quarter last year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences's dividend payout ratio (DPR) is 3,422.22%.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 25,590 shares of the company's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the company's stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock valued at $42,130,461 in the last quarter. 0.29% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Gilead Sciences

Several institutional investors and hedge funds have recently bought and sold shares of GILD. State Street Corp boosted its position in shares of Gilead Sciences by 1.4% during the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock worth $5,044,795,000 after buying an additional 841,776 shares during the period. Wellington Management Group LLP raised its holdings in Gilead Sciences by 50.9% during the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock worth $2,900,921,000 after purchasing an additional 11,665,593 shares in the last quarter. FMR LLC raised its holdings in Gilead Sciences by 79.4% during the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock worth $2,780,329,000 after purchasing an additional 14,680,161 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Gilead Sciences by 2.1% in the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company's stock valued at $2,302,119,000 after buying an additional 574,421 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock valued at $851,743,000 after buying an additional 93,068 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.